Well-Being Report

Overview

The report presents fiscal 2023 record consolidated net sales of 270.8 billion yen and operating income of 40.0 billion yen, alongside a strategy linking six business domains to its Well-being vision. It describes human-capital, supply-chain, and environmental initiatives and sets Sustainability Targets 2030. The report also states a Scope 1 and 2 emissions-reduction target of 46% by 2030 against fiscal 2013 levels for Rohto Pharmaceutical on a non-consolidated basis.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2023-2024
Period: 1 April 2023 – 31 March 2024
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services